High-mobility group box (TOX) antibody a useful tool for the identification of B and T cell subpopulations.

Autor: Maestre L; Monoclonal Antibodies Core Unit, CNIO, Madrid, Spain., García-García JF; Department of Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain., Jiménez S; Monoclonal Antibodies Core Unit, CNIO, Madrid, Spain., Reyes-García AI; Monoclonal Antibodies Core Unit, CNIO, Madrid, Spain., García-González Á; Monoclonal Antibodies Core Unit, CNIO, Madrid, Spain., Montes-Moreno S; Hospital Universitario Marqués de Valdecilla, Pathology Department, Santander, Spain., Arribas AJ; Università della Svizzera Italiana, Institute of Oncology Research, Bellinzona, Switzerland., González-García P; Histopathology Core Unit, CNIO, Madrid, Spain., Caleiras E; Histopathology Core Unit, CNIO, Madrid, Spain., Banham AH; Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom., Piris MÁ; Department of Pathology, Fundación Jiménez Díaz, CIBERONC, Madrid, Spain., Roncador G; Monoclonal Antibodies Core Unit, CNIO, Madrid, Spain.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2020 Feb 27; Vol. 15 (2), pp. e0229743. Date of Electronic Publication: 2020 Feb 27 (Print Publication: 2020).
DOI: 10.1371/journal.pone.0229743
Abstrakt: Thymocyte selection-associated high-mobility group box (TOX) is a DNA-binding factor that is able to regulate transcription by modifying local chromatin structure and modulating the formation of multi-protein complexes. TOX has multiple roles in the development of the adaptive immune system including development of CD4 T cells, NK cells and lymph node organogenesis. However very few antibodies recognizing this molecule have been reported and no extensive study of the expression of TOX in reactive and neoplastic lymphoid tissue has been performed to date. In the present study, we have investigated TOX expression in normal and neoplastic lymphoid tissues using a novel rat monoclonal antibody that recognizes its target molecule in paraffin-embedded tissue sections. A large series of normal tissues and B- and T-cell lymphomas was studied, using whole sections and tissue microarrays. We found that the majority of precursor B/T lymphoblastic, follicular and diffuse large B-cell lymphomas, nodular lymphocyte-predominant Hodgkin lymphomas and angioimmunoblastic T-cell lymphomas strongly expressed the TOX protein. Burkitt and mantle cell lymphomas showed TOX expression in a small percentage of cases. TOX was not found in the majority of chronic lymphocytic leukemia, myelomas, marginal zone lymphomas and classical Hodgkin lymphomas. In conclusion, we describe for the first time the expression of TOX in normal and neoplastic lymphoid tissues. The co-expression of TOX and PD-1 identified in normal and neoplastic T cells is consistent with recent studies identifying TOX as a critical regulator of T-cell exhaustion and a potential immunotherapy target. Its differential expression may be of diagnostic relevance in the differential diagnosis of follicular lymphoma, the identification of the phenotype of diffuse large B-cell lymphoma and the recognition of peripheral T-cell lymphoma with a follicular helper T phenotype.
Competing Interests: The authors have declared that no competing interests exist.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje